SBPH - Spring Bank Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Spring Bank Pharmaceuticals, Inc.

35 Parkwood Drive
Suite 210
Hopkinton, MA 01748
United States

Full Time Employees29

Key Executives

NameTitlePayExercisedYear Born
Mr. Martin J. DriscollPres, CEO & Director618.5kN/A1959
Dr. Radhakrishna P. IyerCo-Founder & Chief Scientific Officer459.2kN/A1950
Dr. Nezam H. AfdhalChief Medical Officer465.5kN/A1957
Mr. Jonathan P. Freve CPA, CPACFO & TreasurerN/AN/A1978
Mr. Donald Mitchell MBAVP of Operations & Corp. Devel.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV). The company is also developing STimulator of INterferon Genes agonist product candidate, including SB 11285, an immunotherapeutic agent for the potential treatment of selected cancers. Spring Bank Pharmaceuticals, Inc. has a collaboration agreement with Gilead Sciences, Inc. for conducting a Phase II clinical trial examining the co-administration of inarigivir and Vemlidy in patients infected with chronic HBV; a research agreement with The National Institute of Allergy and Infectious Diseases to evaluate HBV antisense oligonucleotide compounds; and a collaborative research agreement with the University of Texas Southwestern Medical Center for the evaluation of STimulator of INterferon Gene antagonist compounds in autoimmune disease models. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.

Corporate Governance

Spring Bank Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.